Risk management in the treatment of type 2 diabetes with pioglitazone

References

• Diabetes Atlasthird editionInternational Diabetes Federation2006 Available online at http://www.eatlas.idf.org/
   Google Scholar
• RingborgALindgrenPMartinellMYinDDSchonSStalhammarJPrevalence and incidence of type 2 diabetes and its complications 1996–2003–estimates from Swedish population-based studyDiabet Med200825101178178619046196
   PubMed Web of Science ®Google Scholar
• GrantPJBeneficial effects of metformin on haemostasis and vascular function in manDiabetes Metab2003294 Pt 2S644S652
   Web of Science ®Google Scholar
• ColwellJATreatment of the procoagulant sae in type 2 diabetesEndocrinol Metab Clin North Am20013041011103011727398
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes (UKPDS) Study GroupEffect of intensive blood glucose with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)Lancet199835291318548569742977
   PubMed Web of Science ®Google Scholar
• OhkuboYKishikawaHArakiEIntensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year studyDiabetes Res Clin Pract19952821031177587918
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative GroupPatelAMacMahonSChalmersJIntensive blood glucose control and vascular outcomes in patients with type 2 diabetesN Engl J Med20083582560257218539916
   PubMed Web of Science ®Google Scholar
• Available at: www.diabetes.org.
   Google Scholar
• Action to control Cardiovascular risk in Diabetes Study GroupGersteinHCMillerMEByingtonRPEffects of intensive glucose lowering in type 2 diabetes mellitusN Engl J Med20083582545255918539917
   PubMed Web of Science ®Google Scholar
• Cugnet-AnceauCBauduceauBGlycaemic control and cardiovascular morbi-mortality: The contribution of the 2008 studiesAnn Endocrinol (Paris)2009 In press
   Web of Science ®Google Scholar
• SjöholmANyströmTEndothelial inflammation in insulin resistanceLancet2005365945961061215708106
   PubMed Web of Science ®Google Scholar
• DormandyJACharbonnelBEcklandDJPROactive investigatorsSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialLancet20053661279128616214598
   PubMed Web of Science ®Google Scholar
• NiessenSENichollsJWolskiKPERISCOPE InvestigatorsComparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trialJAMA2008299131561157418378631
   PubMed Web of Science ®Google Scholar
• HomePDPocockSJBeck-NielsenHRosiglitazone evaluated for cardiovascular outcome-an interim analysisN Engl J Med2007357283817551159
   PubMed Web of Science ®Google Scholar
• AronoffSRosenblattSBraithwaiteSEganJWMathisenALSchneiderRLPioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study GroupDiabetes Care200023111605101111092281
   PubMed Web of Science ®Google Scholar
• TanMHGlazerNBJohnsDWidelMGilmoreKJPioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetesCurr Med Res Opin200420572372815140339
   PubMed Web of Science ®Google Scholar
• ScherbaumWAGökeBGerman Pioglitazone Study GroupMetabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled studyHorm Metab Res2002341058959512439788
   PubMed Web of Science ®Google Scholar
• HerzMJohnsDReviriegoJA randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitusClin Ther20032541074109512809958
   PubMed Web of Science ®Google Scholar
• RosenblattSMiskinBGlazerNBPrinceMJRobertsonKEPioglitazone 026 Study GroupThe impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitusCoron Artery Dis200112541342311491207
   PubMed Web of Science ®Google Scholar
• PavoIJermendyGVarkonyiTTEffect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetesJ Clin Endocrinol Metab20038841637164512679450
   PubMed Web of Science ®Google Scholar
• SchernthanerGMatthewsDRCharbonnelBHanefeldMBrunettiPQuartet Study GroupEfficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trialJ Clin Endocrinol Metab200489126068607615579760
   PubMed Web of Science ®Google Scholar
• WalterHLübbenGPotential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitusDrugs200565111315610048
   PubMed Web of Science ®Google Scholar
• TanMHJohnsDStrandJHalseJGLAC Study GroupSustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycae mic control, and lipid profiles in patients with Type 2 diabetesDiabet Med200421885986615270789
   PubMed Web of Science ®Google Scholar
• TanMJohnsDGonzálezGálvezGLAD Study GroupEffects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trialClin Ther200426568069315220012
   PubMed Web of Science ®Google Scholar
• RizzoMChristERRiniGBSpinasGABerneisKThe differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?Expert Opin Pharmacother20089132295230318710354
   PubMed Web of Science ®Google Scholar
• DerosaGD‘AngeloARagonesiPDMetabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metforminIntern Med J2007372798617229249
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFGaddiAMetabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trialClin Ther200426574475415220018
   PubMed Web of Science ®Google Scholar
• Yki-JärvinenHThiazolidinedionesN Engl J Med2004351111106111815356308
   PubMed Web of Science ®Google Scholar
• NegroRDazziDHassanHPezzarossaAPioglitazone reduces blood pressure in non-dipping diabetic patientsMinerva Endocrinol2004291111715258553
   PubMedGoogle Scholar
• DerosaGCiceroAFD’AngeloAThiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepirideHypertens Res2005281191792416555581
   PubMed Web of Science ®Google Scholar
• DerosaGFogariECiceroAFBlood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metforminHypertens Res200730538739417587750
   PubMed Web of Science ®Google Scholar
• HanefeldMBrunettiPSchernthanerGHMatthewsDRCharbonnelBHQUARTET Study GroupOne-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetesDiabetes Care200427114114714693980
   PubMed Web of Science ®Google Scholar
• MatthewsDRCharbonnelBHHanefeldMBrunettiPSchernthanerGLong-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative studyDiabetes Metab Res Rev200521216717415386821
   PubMed Web of Science ®Google Scholar
• ForstTHohbergCFuellertSDPharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetesHorm Metab Res200537852152716138267
   PubMed Web of Science ®Google Scholar
• MazzoneTMeyerPMFeinsteinSBEffect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trialJAMA2006296212572258117101640
   PubMed Web of Science ®Google Scholar
• HorioTSuzukiMTakamisawaIPioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertensionAm J Hypertens20051812 Pt 11626163016364837
   PubMed Web of Science ®Google Scholar
• NakayamaTKomiyamaNYokoyamaMPioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: A randomized prospective study using intravascular ultrasoundInt J Cardiol2008 Sep 23 Epub ahead of print
   Web of Science ®Google Scholar
• DerosaGD’AngeloARagonesiPDMetformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndromeJ Clin Pharm Ther200631437538316882108
   PubMed Web of Science ®Google Scholar
• EinhornDRendellMRosenzweigJPioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study GroupClin Ther200022121395140911192132
   PubMed Web of Science ®Google Scholar
• NestoRWBellDBonowROFonsecaVThiazolidinedione use, fluid retention and congestive heart failure. A consensus statement from the American Heart association and American Diabetes AssociationDiabetes Care200527125626314693998
   PubMed Web of Science ®Google Scholar
• EmotoMAnnoTSatoYTroglitazone treatement increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytesDiabetes2001501166117011334422
   PubMed Web of Science ®Google Scholar
• El MuayedMLavisVRSafiHJUse of glitazone in cardiac patients: a case for B-type natriuretic peptide monitoring?Am J Cardiol20049360060214996586
   PubMed Web of Science ®Google Scholar
• SambanisCTziomalosKKountanaEEffect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetesActa Diabetol2008451233017768592
   PubMed Web of Science ®Google Scholar
• ErdmannEHeart failure with thiazolidinedione treatment: what do we know today?Dtsch Med Wochenschr2009134415415819148858
   PubMed Web of Science ®Google Scholar
• McDonoughAKRosenthalRSCaoXSaagKGThe effect of thiazolidinediones on BMD and osteoporosisNat Clin Pract Endocrinol Metab20084950751318695700
   PubMedGoogle Scholar
• SchwartzAVSellmeyerDEVittinghoffEThiazolidinedione use and bone loss in older diabetic adultsJ Clin Endocrinol Metab2006913349335416608888
   PubMed Web of Science ®Google Scholar
• WatanabeSTakeuchiYFukumotoSFujitaHDecrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patientsJ Bone Miner Metab20032116617112720051
   PubMed Web of Science ®Google Scholar
• GlintborgDAndersenMHagenCAssociation of pioglitazone treatment with decrease bone mineral density in obese premenopausal patients with policistic ovary syndrome: a randomized, placebo controlled trialJ Clin Endocrinol Metab20089351696170118285411
   PubMed Web of Science ®Google Scholar
• KempnaPHoferGMullisPEFluckCEPioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2Mol Pharmacol20077178779817138841
   PubMed Web of Science ®Google Scholar
• GholamineBShafieiMMotevallianMMahmoudianMEffects of pioglitazone on erectile dysfunction in sildenafil poor-responders: a randomized, controlled studyJ Pharm Pharmaceut Sci20081112231
   Web of Science ®Google Scholar
• SpanheimerRPerezAKupferSThe effects of pioglitazone vs glyburide on glycemic control in patients with type 2 diabetes in a 3-year randomized double-blind trialDiab Vasc Dis Res200631394416784180
   PubMedGoogle Scholar
• UmpierrezGIssaMVlajnicAGlimepiride versus pioglitazone combination therapy in subjects with type diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trialCurr Med Res Opin20062275175916684436
   PubMed Web of Science ®Google Scholar
• CharbonellBHSchernthanerGBrunettiPLong-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metfomin in patients with type 2 diabetesDiabetologia2005481093110415889234
   PubMed Web of Science ®Google Scholar
• KupferSSpanheimerRPerezACardiovascular safety profile of pioglitazone vs glyburide: results from a 3-year, randomized, double blind trial [abstract] 66th Annual Scientific Session of The American Diabetes Association
   Google Scholar
• HanefeldMBelcherGSafety profile of pioglitazoneInt J Clin Pract Suppl2001121273111594241
   PubMedGoogle Scholar
• SmithSRDe JongeLVolaufovaJLiYXieHBrayGAEffect of pioglitazone on body composition and energy expenditure: a randomized controlled trialMetabolism2005541243215562376
   PubMed Web of Science ®Google Scholar
• DerosaGMereuRSalvadeoSATPioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramineInter Med200948265271
   Web of Science ®Google Scholar
• NissenSEWolsklKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med20073562457247117517853
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKFurbergCDLong term risk of cardiovascular events with rosiglitazone. A meta-analysisJAMA2007298101189119517848653
   PubMed Web of Science ®Google Scholar
• Division of Metabolism and Endocrine Products and Office of Surveillance and Epidemology, US Food and Drug AdministrationFDA Briefing Document: joint meeting of the Endocrinologic and and Metabolic Drugs Advisory Committee available at www.fda.gov
   Google Scholar
• LincoffAMWolskiKNichollsSJNissenSEPioglitazone and the risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trialsJAMA2007298101180118717848652
   PubMed Web of Science ®Google Scholar
• RajagopalanPPerezAYeZKhanMMurrayFTPioglitazone is effective therapy for elderly patients with type 2 diabetes mellitusDrugs Aging20042125927115012171
   PubMed Web of Science ®Google Scholar
• MaegawaHSitagliptin added to ongoing treatment with pioglitazone study up to 52 weeks in Japanese patients with T2DM [abstract] European Association for the Study Diabetes2008 Abstract 910
   Google Scholar
• ValentineWJTuckerDPalmerAJMinshallMEFoosVSilbermanCLong-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: A US Analysis Based on PROactiveValue Health2008 Jul 24 Epub ahead of print
   Web of Science ®Google Scholar